COMP <GO>
HSTM vs NVDA // EV/EBITDA & P/E VALUATION
HealthStream Inc. (NASDAQ) VS. NVIDIA Corporation (NASDAQ) • 15-METRIC TALLY: HSTM 4
— NVDA 7
▲ EV/EBITDA & P/E VALUATION LEADER: NVDA
LAST: $33.80 (+0.21%) • MKT CAP: $1.03B
valuation
42.7x
LAST: $213.66 (-0.80%) • MKT CAP: $5.15T
valuation
23.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HSTM VS. NVDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HSTM | NVDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.67% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.00% | 65.06% | -60.06 | NVDA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 42.7x | 23.2x | +19.49 | NVDA | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | 2.58% | +3.19 | HSTM | /fcf-yield <GO> |
| Operating Margin | 6.70% | 65.21% | -58.51 | NVDA | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 63.66% | -57.66 | NVDA | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 83.38% | -79.08 | NVDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.36% | 0.02% | +0.34 | HSTM | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 19.52 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | HSTM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 9.01% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.1 | 51.1 | +9.05 | HSTM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 2.04 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 52.5x | 17.0x | +35.48 | NVDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.03B | $5.15T | -$5.15T | NVDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HSTM REV | NVDA REV | HSTM GROSS % | NVDA GROSS % | HSTM FCF | NVDA FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $215.94B | — | 71.1% | — | $96.68B |
| FY 2025 | $304.1M | $130.50B | — | 75.0% | $59.6M | $60.85B |
| FY 2024 | $291.6M | $60.92B | — | 72.7% | $56.3M | $27.02B |
| FY 2023 | $279.1M | $26.97B | — | 56.9% | $64.0M | $3.81B |
| FY 2022 | — | $26.91B | — | 64.9% | — | $8.13B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HSTM // BETA —
NVDA // BETA 2.04